A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. by Patel, Pretesh R et al.
UC San Diego
UC San Diego Previously Published Works
Title
A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell 
lung cancer.
Permalink
https://escholarship.org/uc/item/6bz8w62g
Authors
Patel, Pretesh R
Yoo, David S
Niibe, Yuzuru
et al.
Publication Date
2012
DOI
10.1155/2012/480961
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Hindawi Publishing Corporation
Pulmonary Medicine
Volume 2012, Article ID 480961, 7 pages
doi:10.1155/2012/480961
Review Article
A Call for the Aggressive Treatment of Oligometastatic and
Oligo-Recurrent Non-Small Cell Lung Cancer
Pretesh R. Patel,1 David S. Yoo,1 Yuzuru Niibe,2 James J. Urbanic,3 and Joseph K. Salama1
1Department of Radiation Oncology, Duke University, P.O. Box 3085, Durham NC 27713, USA
2Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara 252-0374, Japan
3Department of Radiation Oncology, Wake Forest University, Winston-Salem, NC 27157, USA
Correspondence should be addressed to Joseph K. Salama, joseph.salama@duke.edu
Received 3 August 2012; Accepted 11 September 2012
Academic Editor: Hideomi Yamashita
Copyright © 2012 Pretesh R. Patel et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis. Clinical evidence suggests the existence of an
intermediate, or oligometastatic, state when metastases are limited in number and/or location. In addition, following initial
curative therapy, many patients present with limited metastatic disease, or oligo-recurrence. Metastasis-directed, anti-cancer
therapies may benefit these patients. A growing evidence-base supports the use of hypofractionated, image-guided radiotherapy
(HIGRT) for a variety of malignant conditions including inoperable stage I NSCLC and many metastatic sites. When surgical
resection is not possible, HIGRT offers an effective alternative for local treatment of limited metastatic disease. Early studies
have produced promising results when HIGRT was delivered to all known sites of disease in patients with oligometastatic/oligo-
recurrent NSCLC. In a population of patients formerly considered rapidly terminal, these studies report five year overall
survival rates of 13–22%. HIGRT for metastatic NSCLC warrants further study. We call for large, intergroup, and even
international randomized trials incorporating HIGRT and other metastasis-directed therapies into the treatment of patients with
oligometastatic/oligo-recurrent NSCLC.
1. Introduction
Lung cancer is the most lethal malignant tumor. Affecting
over one million people each year, it results in approximately
951,000 deaths [1]. Eighty-five percent of lung cancer
patients have non-small cell lung cancer (NSCLC), and about
40% of those will present with distant metastatic disease [2].
The current standard therapy for most metastatic NSCLC
patients is doublet chemotherapy. Contemporary regimens,
such as cisplatin and docetaxel, demonstrate superior out-
comes compared to regimens of the last decade [3, 4]. Even
with the most effective cytotoxic agents only 30% of patients
respond to therapy and the median survival from diagnosis
is approximately 1 year [5–7]. Worse still, the response to
second line therapy is poor (7–11%) with a median survival
of 8 months at best [8, 9]. Herein, we call for the systematic
study of new approaches and integration of all available
therapeutic modalities in the management of this humbling
disease.
2. Oligometastases and Oligo-Recurrence
It has been proposed that the natural history of metastatic
spread may proceed stepwise, and there exists an oligome-
tastatic state when metastases are limited in number and/or
location and therefore amenable to loco-regional therapy
[10]. In other cases, when subclinical disease is eradicated
by systemic therapy, the clinically apparent metastases may
be considered “residual” oligometastases, which may serve
as a nidus for further dissemination [11]. Furthermore,
following initial curative therapy, a large number of patients
will recur, and many will have recurrences limited in number
and destination organ, that is, oligo-recurrence [12]. The
key distinction between oligo-recurrence and oligometastasis
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is that the primary tumor is controlled in the former
and a small institutional series suggests more favorable
prognosis [13]. Metastasis-directed anti-cancer therapies
may benefit patients with de novo oligometastases, induced
oligometastases, or oligo-recurrence.
A fact not often appreciated is that the oligometastat-
ic/oligo-recurrent phenotype is common. Widespread use of
more sensitive staging studies, such as PET/CT, has led to
a growing incidence of stage IV NSCLC [14]. In addition,
patients receiving systemic therapy for stage IV NSCLC often
progress only in sites of known metastases. An analysis of
metastatic NSCLC patients treated in a phase II protocol
with oxaliplatin and paclitaxel at the University of Chicago,
found that 50% (19/38) of patients had stable or progressive
disease only in sites that were initially involved with tumor
without developing new metastatic lesions [15]. This number
grew to 65% (11/17) in the subset with 4 or fewer metastases.
Similarly, an analysis of patients with limited metastatic
NSCLC from the University of Colorado demonstrated that
the patterns of progression are primarily within known sites
of disease [16].
Tailored systemic therapy and targeted agents may fur-
ther improve the control of subclinical disease and induce
an oligometastatic state. Non-squamous NSCLC responds
favorably to pemetrexed-based systemic regimens [17, 18].
The addition of a targeted antiangiogenic agent, bevaci-
zumab, to carboplatin and paclitaxel [19] has resulted in
improved survival. Patients with epidermal growth factor
receptor (EGFR) mutations have superior progressive free
survival when treated with EGFR inhibitors [20]. Simi-
larly, identification of the EML4-ALK mutation results in
superior survival when crizotinib, a small molecule ALK
inhibitor, is included in the systemic therapy regimen [21].
Whole genome sequencing of NSCLC is underway [22] and
may lead to identification of novel subtypes and personalized
therapies.
Selected patients with limited metastatic disease have
achieved cure and prolonged palliation with local and
regional treatment. For example, resection of brain [33], lung
[34], liver [35], and adrenal [36] metastases have resulted
in long term cure of patients with metastatic NSCLC. In
addition, aggressive treatment of intracranial metastases with
stereotactic radiosurgery (SRS) has resulted in high long
term disease control rates [37]. These long term survivors
are clinical proof of the oligometastatic/oligo-recurrent state.
Moreover, with improving systemic therapies, the control of
oligometastases will play a larger role in determining patient
outcome. Even if cure rates remain low, local treatment
could prevent or ameliorate morbidity related to local tumor
proliferation.
3. Hypofractionated, Image-Guided
Radiotherapy (HIGRT)
For patients who are not candidates for surgical excision
of metastatic disease, radiotherapy (RT) is an effective
alternative local therapy. Fractionated RT has long played
a role in the palliation of metastatic NSCLC. Technological
improvements over the past decade have led to modern
RT delivery systems capable of unprecedented precision
and accuracy. Stereotactic, high-dose, single fraction brain
irradiation, or stereotactic radiosurgery (SRS), was once
considered the vanguard of RT. Today, improvements in
tumor target delineation, RT dosimetry, respiratory motion
management, and tumor targeting have led to the prolif-
eration of brain SRS and stereotactic body radiotherapy
(SBRT). SBRT, or stereotactic ablative radiotherapy (SABR),
is perhaps more aptly described as hypofractionated, image-
guided radiotherapy (HIGRT) now that stereotactic frames
are rarely used.
An exploding body of literature supports the use of
HIGRT for a variety of malignant conditions. Brain SRS is
associated with excellent local control without significant
toxicity. In fact, 80–95% of tumors less than 2 cm were per-
manently controlled by single doses of 18–20Gy regardless of
tumor type [38]. The local control for lung lesions is similarly
excellent. Phase I and II American studies have demonstrated
greater than 90% primary tumor control following HIGRT
for medically inoperable NSCLC [39]. Japanese studies have
also showed overall local control of 89.6% with an NCI-CTC
grade 3–5 complication rate of only 2.1% [40]. Evidence-
based guidelines now recommend definitive lung HIGRT for
medically inoperable stage I NSCLC [41]. Promising results
are also emerging to support the use of definitive HIGRT for
prostate cancer [42, 43], and inoperable pancreatic cancer
[44]. Lung [45, 46], liver [47, 48], and spinal [49–53] metas-
tases have been effectively treated with HIGRT, including
classically radioresistant histologies such as melanoma [54]
and renal cell carcinoma [55]. What is striking in all these
studies is that a high probability of durable treated metastasis
control is possible with the use of high conformal, precisely
targeted, (usually) substantially hypofractionated treatment
courses regardless of metastatic site or histology. Equally
encouraging has been the relative limited toxicity reported
with these treatments.
Biologically, it is not clear why hypofractionated radio-
therapy results in high tumor control rates. Hypofraction-
ated radiotherapy has radiobiological advantages over stan-
dard fractionated RT including a greater potential cell kill
and reduction in the deleterious effect of tumor proliferation
during RT. Large radiation doses are thought to not only
enhance tumor cell kill, but also engage sphingomyelin-
based endothelial mechanisms of tumor control [56, 57].
Additionally, recent reports have identified immune-medi-
ated mechanisms that may play a key role in controlling
tumors following hypofractionated RT [58, 59]. The use of
ablative radiotherapy in concert with immunomodulatory
therapies have demonstrated an abscopal effect, that is, a
response in nonirradiated metastases [60, 61]. This abscopal
effect may become particularly relevant in the treatment of
oligometastatic disease where the potentiation of an immune
response could be particularly efficacious.
4. Metastasis-Directed HIGRT
Data are now beginning to emerge that the aggressive treat-
ment of both the primary tumor and metastases with RT
as an integral component can result in improved outcomes.
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Median survival following conventional radiotherapy for
brain metastases is 3–6 months and 1-year survival of 8%
in a large retrospective series [62]. Even those with only 1-2
brain metastases have a 2-year survival of only 6% [63]. A
number of studies have focused on the subgroup of patients
with limited intracranial metastases from NSCLC (Table 1).
In these studies, aggressive treatment of metachronous brain
metastases in NSCLC patients, that is oligo-recurrence, with-
out extracranial disease produced 5-year survival of 13.2%
[23]. Additionally, in those with synchronous solitary brain
metastases, aggressive treatment of intracranial metastases
with radiosurgery as well aggressive treatment of intratho-
racic disease resulted in 21% 5-year survival [24]. A recent
review on this topic concludes that aggressive brain and
thoracic treatment should be offered to these patients
[64].
Reports, primarily from single institutions, have demon-
strated favorable outcomes when patients with limited
extracranial metastatic NSCLC received aggressive therapy
to all known cancer sites (Table 1) [13, 26–29]. An analysis
from the University of Rochester reported median survivals
of patients with limited metastatic NSCLC treated with
HIGRT to be similar to that of stage III NSCLC patients
and exhibiting 5-year survival of 14% [26]. Twenty-five
patients from the University of Chicago with a median of two
extracranial metastases underwent HIGRT and had median
survival similar to that seen in stage III patients at 23-month
and 18-month overall survival of 53% [28]. Interestingly,
those treated with prior systemic therapy, those progressing
through chemotherapy immediately prior to HIGRT, and
nonadenocarcinoma histology were associated with worse
outcomes.
Looking at all these data, one message stands clear; all
known cancer sites must be treated to benefit patients with
limited metastatic NSCLC. An analysis of the M.D. Anderson
Cancer Center Registry, presented at ASCO 2008 (abstr no.
19020), supports aggressive treatment of primary tumors
and regional nodes in patients with metastatic NSCLC.
This study found that patients with solitary brain metas-
tases from NSCLC who received curative-intent thoracic
locoregional treatment with either surgery or concomitant
chemoradiotherapy median survival improved from 7 to 30
months (P = 0.00186), compared to those who did not.
Additionally, this survival advantage was not statistically
significant in patients with untreated extracranial metastases.
Furthermore, patients with solitary brain metastases treated
with surgical resection [13]or radiosurgery [24]significantly
benefited from treatment to the primary tumor in addition
to aggressive treatment of metastatic disease. This highlights
the need to treat all known metastatic deposits whenever
possible.
5. Metastasis-Directed HIGRT:
Prospective Trials
Based on the promising data, it is clear that further study
is needed to carefully integrate these novel RT techniques
with standard systemic therapy platforms for patients with
metastatic NSCLC. Attempts have been made to prospec-
tively study HIGRT (Table 2). Each study has asked different
questions so it is worth reviewing each in some detail.
The NCCTG initiated a randomized phase III study to
test the hypothesis that RT to all known sites of disease
following 4–6 cycles of systemic therapy in NSCLC patients
with one to three metastatic sites would result in improved
overall survival [30]. Following the completion of non-
standardized systemic therapy, patients were randomized to
observation or RT to all known sites of disease. The RT
schemawas 60Gy in 2Gy fractions or 45Gy in 3Gy fractions.
The study was closed due to poor accrual. This was likely due
to randomization following all chemotherapy, a time when
patients and physicians are looking forward to an end of
treatment. Additionally, the protracted courses of radiation
over a six-week time span with historically limited control
rates may have contributed.
The University of Chicago initiated a randomized phase
II study in patients with 1–5 NSCLC metastases, testing
the hypothesis that HIGRT to all known sites of metastatic
disease during the third and fourth cycles of systemic therapy
would improve progression-free and overall survival [31].
Based on prior institutional studies, cisplatin and docetaxel
were used as the chemotherapy backbone and RT was given
in 5Gy fractions to a total dose of 50Gy. Additionally,
conventionally fractionated radiotherapy (60Gy in 2Gy
fractions) was allowed when combined with systemic therapy
for stage III-type intra-thoracic disease. Different from the
NCCTG study, this study randomized patients prior to any
therapy. This study too, had difficulty accruing, and closed
prior to meeting the accrual goal.
Currently, a single arm phase II study at Wake Forest
University is ongoing to test the hypothesis that HIGRT to
all known extracranial metastasis following the completion
of appropriate systemic therapy can improve outcomes of
limited metastatic NSCLC [32]. All patients (with either de
novo or recurrent metastases) receive 3 to 6 cycles of systemic
therapy at the discretion of the treating medical oncologist
and must have stable disease or a partial response. Similar
to the University of Chicago study, fractionated therapy
can be used to treat stage 3 type intra-thoracic disease.
Different from the NCCTG study, hypofractionated image-
guided radiotherapy is used which allows for the delivery of
metastasis-directed therapy quickly. This study continues to
accrue at several centers in North Carolina, USA. Currently,
approximately 15 out of a planned 54 patients have been
enrolled over the past 18 months.
6. Metastasis-Directed HIGRT: A Call to Action
Despite difficulties with accrual in this patient population,
there is still a need for randomized studies. The slow accrual
of these studies is attributable to shortfalls in study design,
and an unfamiliarity among practitioners about the encour-
aging data is already available for this common problem.
Although limited metastatic disease is relatively common,
there is considerable heterogeneity with regard to location
and number of metastases. Therefore, more flexible radio-
therapy dosing schedules are needed. Likewise, flexibility in
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Table 1: Selected series for the comprehensive treatment of metastatic NSCLC.
Study N Metastatic sites Treatments 1-year PFS 5-year OS
University of Maryland
[23]
72 Brain (metachronous) SRS 13.2%
University of Maryland
[24]
42 Brain (synchronous) SRS, TS, RT, CRT, HIGRT 21%
Hopital Louis Pradel
Hospices Civils de Lyon,
Lyonnce [25]
51 Brain (synchronous) BS, TS, RT, CRT 42% (BS + others)
versus 5% (BS only)∗
University of Rochester
[26]
38 Multisite, 1–8 metastases HIGRT 14%
Rush University Medical
Center [27]
23 Multi-site, 1-2 metastases TS, RT, HIGRT 22%
University of Chicago [28] 25 Multi-site, 1–5 metastases HIGRT (3–10 fx) 28% 53% (18mo)
Maastricht University
Medical Center [29]
39 Brain, bone, adrenal TS, SRS, RT, HIGRT 24%∗
∗2 yr estimates; SRS: stereotactic radiosurgery; BS: brain surgery; TS: thoracic Surgery; RT: radiotherapy; CRT: chemoradiotherapy; HIGRT: hypofractionated
image-guided radiotherapy.
Table 2: Prospective study characteristics for comprehensive treatment of limited metastatic NSCLC with hypofractionated RT.
Study group Inclusion Systemic therapy Radiotherapy Outcome
NCCTG [30] 1–3 metastatic sites Nonstandardized
60Gy (2Gy fx)
45Gy (3Gy fx)
Closed due to poor
accrual
University of Chicago
[31]
1–5 metastatic sites
Cisplatin
docetaxel
50Gy (5Gy fx)
60Gy (2Gy fx) if
Combined with CT
Closed due to poor
accrual
Wake Forest
University [32]
Limited metastatic
NSCLC
Non-standardized
HIGRT or
conventional RT
Open to accrual
the systemic therapy is also needed as tailored and targeted
regimens gain favor. The currently open Wake Forest trial
takes advantage of both of these issues by allowing selection
of systemic therapy at the discretion of the treating medical
oncologist and selection of the radiotherapy dose based
on what the treating radiation oncologist perceives to be
achievable. The most commonly used doses on the Wake
Forest trial thus far have been 50Gy in 5 fractions or 50Gy in
10 fractions prescribed to the PTV margin.
Perhaps most importantly, study design should reflect
thoughtful consideration of the ethical issues surrounding
aggressive therapy for metastatic NSCLC. Specifically, studies
that prioritize patient and physician equipoise are most
likely to meet accrual goals. An ideal trial would register
patients during the first two cycles of chemotherapy, but
only randomize following restaging showing no evidence
of progression. This would allow selection of patients with
truly oligometastatic disease where chemotherapy would
likely have impacted micrometastatic disease. Patients would
then be randomized to (1) HIGRT followed by further
systemic therapy or (2) systemic therapy with conventional
RT reserved for standard palliative indications. Biologic
correlative studies analyzing blood and tissue would be
essential.
Furthermore, emerging data may improve patient selec-
tion beyond simple number and location of metastases.
Favorable clinical factors such as better performance status
[13], limited nodal involvement [65], no prior systemic
therapy [28], lack of progression on systemic therapy [28],
lack of extracranial metastases [66], metachronous (versus
synchronous) brain metastases [67], and 1–3 metastases [28]
have been identified. Histologic features such as nonsqua-
mous NSCLC [28, 65] and targetable molecular mutations
may also guide patient selection. Serum markers such as
low carcinoembryonic antigen level [65] or upregulated Inf-
gamma [68] appear to be associated with improved out-
comes. An analysis of patients with limited metastases of any
histology found that expression of microRNA 200c predicted
for true oligometastatic disease with no progression or
progression limited in number and destination organs [69].
Beyond improved tools to select patients who may derive
survival benefits from this therapy, there are other reasons
when HIGRT to all known metastatic sites may be beneficial.
As noted above, HIGRT is associated with limited toxicity
and favorable progression free-survival. For patients unable
to tolerate systemic cytotoxic therapy, HIGRT may act as
another “line” of therapy. This is an important consideration
given the extremely limited activity of second and third
line systemic therapies. Alternatively, early evidence suggests
HIGRT may sensitize patients to systemic therapy due to
the immunomodulatory abscopal effect (as noted above).
If confirmed in NSCLC, such an effect could enhance the
role of HIGRT for patients with limited or not-so limited
metastatic NSCLC.
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Additionally, ideal clinical trials may ultimately need
to be developed that test the concept of aggressive local
therapy with minimal toxicity in general rather than simply
a radiotherapy approach to this disease. This should include
combinations of surgery, thermal ablation, HIGRT, radio
or chemoembolization, and radiotherapy tailored to each
individual patient. Additionally, should patients progress
with new sites of disease, metastasis-directed therapies with
nonoverlapping toxicity profiles should be considered. This
will be particularly useful for patients who have exhausted
radiotherapy options due to issues of cumulative dose. In this
way patients can be rendered free of macroscopically visible
disease and the use of chemotherapy can be appropriately
relegated to the goal of the eradication of microscopic
disease.
7. Conclusion
From the data above it is clear that in appropriately selected
patients, aggressive treatment of extracranial metastases and
primary tumors can lead to meaningful improvements in
overall and progression-free survival. Studies need to be
conducted to explore the impact of these therapies. Clearly
this will take a coordinated effort. It is unlikely that single
cooperative groups will be able to independently accrue and
complete these studies. It will take not only an intergroup
effort, but also an international effort to complete these
studies. The time to conduct these studies is now.
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